Welcome to our dedicated page for Citius Oncology SEC filings (Ticker: CTOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Citius Oncology, Inc. (Nasdaq: CTOR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an emerging growth company incorporated in Delaware and listed on Nasdaq, Citius Oncology reports material corporate events, governance decisions, and securities transactions through forms such as 8‑K, proxy statements, and registration-related documents.
Recent Form 8‑K filings describe events including amendments to the company’s 2024 Omnibus Stock Incentive Plan and unregistered sales of equity securities. For example, Citius Oncology has reported an increase in the number of shares of common stock authorized for issuance under the 2024 Omnibus Stock Incentive Plan and the issuance of warrants to a financial advisor in a private placement. Another 8‑K details stockholder voting results at the 2025 annual meeting, including the election of Class I directors, approval of the incentive plan amendment, and ratification of the independent registered public accounting firm.
The company’s definitive proxy statement on Schedule 14A outlines the agenda and voting procedures for the annual meeting, the proposals presented to stockholders, and information on the number of shares outstanding and entitled to vote. Regulation FD disclosures, such as the posting of an updated corporate presentation, are also reported via Form 8‑K and incorporated by reference.
Through Stock Titan, these filings are organized so that investors can quickly locate specific document types, such as current reports on material events, proxy materials, and other disclosures that complement Citius Oncology’s press releases about LYMPHIR™ (denileukin diftitox-cxdl) and its commercialization. AI-powered tools on the platform can assist users by summarizing lengthy documents, highlighting key items like equity plan changes, warrant issuances, and governance decisions, and helping readers understand how these regulatory filings relate to the company’s broader oncology strategy.
Suren G. Dutia, a director of Citius Oncology, acquired 300,000 restricted shares on 09/19/2025 at no cash price and reports beneficial ownership of 300,000 shares directly following the grant. The Form 4 also discloses two stock option holdings: a $1.07 exercise-price option for 125,000 shares granted 12/12/2024 that vests one-third annually, and a fully vested $2.15 exercise-price option for 150,000 shares. The restricted shares vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to continued service.
Citius Oncology director Eugene Myron Holuka acquired 300,000 restricted shares on 09/19/2025 and holds outstanding stock options totaling 275,000 shares. The restricted stock award was granted at no cash price and will vest in three substantially equal annual installments beginning one year after grant, subject to continued service. The reporting person also holds a $1.07 strike option for 125,000 shares (granted 12/12/2024, vesting 1/3 annually) and a fully vested $2.15 strike option for 150,000 shares. Following the reported transactions, the reporting person beneficially owns 300,000 shares and options on 275,000 shares directly.
Citius Oncology, Inc. (CTOR) filed a Registration Statement on Form S-8 to register securities for an employee benefit plan. The filing incorporates by reference the company’s prior annual and quarterly reports and certain current reports listed in the document, and cites a Certificate of Amendment to the Certificate of Incorporation filed in Delaware on
Citius Oncology, Inc. reported that it issued warrants to a financial advisor to purchase up to 360,000 shares of common stock. These warrants have an exercise price of $2.1875 per share, become exercisable on March 10, 2026, and expire on March 10, 2031, and were issued in a private placement under Section 4(a)(2) of the Securities Act.
The board also approved an amendment to the company’s 2024 Omnibus Stock Incentive Plan, increasing the shares of common stock reserved for issuance under the plan from an aggregate of 15,000,000 shares to an aggregate of 30,000,000 shares. Aside from this increase in the share reserve, no other terms of the plan were changed.
Citius Pharmaceuticals, Inc. amended its Schedule 13D to reflect a registered direct offering on September 10, 2025 that issued 5,142,858 new common shares of Citius Oncology, Inc. After that issuance the reporting person, Citius Pharmaceuticals, Inc., beneficially owns 66,049,615 shares, representing approximately 79.1% of the issued and outstanding common stock based on a total of 83,513,442 shares. The filing states the reporting person has sole voting and dispositive power over those shares. The amendment updates prior Schedule 13D filings to give effect to the new issuance.